COMMUNIQUÉS West-GlobeNewswire

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
08/09/2025
WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN [...]
BlueGenesLab Expands Genetic Panel to Include Three New GLP-1–Related Genes
08/09/2025
SCOTTSDALE, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BlueGenesLab , a precision genomics company headquartered in Scottsdale, Arizona, today announced the addition of three genes to its clinical testing panel that [...]
Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals
08/09/2025
Partnership unlocks exclusive tokenization rights, a four percent (4%) annual yield target on physical bullion, revenue share tied to leasing volumes and the creation of a groundbreaking institutionalized asset [...]
KFSHRC Launches Middle East’s First Smart Neuroscience Ward With Electromagnetic Shielding for Ultra-Precise Brain Monitoring
08/09/2025
RIYADH, Saudi Arabia, Sept. 08, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has inaugurated the Middle East’s first Smart Neuroscience Ward, a pioneering facility that [...]
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
08/09/2025
PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”) , expanding evidence [...]
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
08/09/2025
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well tolerated Patients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom [...]
Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
08/09/2025
HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology [...]
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
08/09/2025
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support further Phase 3 [...]
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
08/09/2025
Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) [...]
Ocular Therapeutix™ to Host Investor Day on September 30, 2025
08/09/2025
Company to highlight ongoing AXPAXLI™ wet AMD registrational program, strategy and next steps in NPDR and DME, and global commercial opportunity for AXPAXLI Event to feature global retinal disease experts Dr. Arshad M. [...]
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025
08/09/2025
Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for fibromyalgia in over 15 years Two pivotal Phase 3 studies demonstrated Tonmya significantly [...]
Attralus Presents New Data on Its Pan-Amyloid Diagnostic Imaging Candidates at ASNC 2025
08/09/2025
124 I-evuzamitide, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected of or diagnosed with cardiac amyloidosis in [...]
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants
08/09/2025
iMDx’s ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previously GraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026 NASHVILLE, Tenn., Sept. 08, [...]
EDAP Receives HIFU Reimbursement for Prostate Cancer in France
08/09/2025
Focal One Robotic HIFU procedure now covered under France’s national universal health system Reimbursement milestone allows increased patient access to Focal One Robotic HIFU AUSTIN, Texas, September 8, 2025 - EDAP TMS [...]
Picard Medical, Inc. Announces Presentation at H.C. Wainwright Global Investment Conference
08/09/2025
TUCSON, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that Patrick NJ Schnegelsberg, Chief Executive Officer, will present in-person at [...]
Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
08/09/2025
-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics [...]
Kraig Biocraft Laboratories Appoints Kenneth Le as Managing Director of Prodigy Silk
08/09/2025
ANN ARBOR, Mich., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, is happy to announce the appointment of Mr. [...]
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database
08/09/2025
5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partners New hospital-based data seeks to further differentiate pending kitted assay that measures biomarker for [...]
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025
08/09/2025
• Clinical data demonstrated administration of AGA2115 drove dose-dependent increases in bone mineral density • The Company and collaborators also presented data from non-human primate and mouse models WESTLAKE VILLAGE [...]

Pages